ArticleProbiotics and antimicrobial proteins2026
Pediococcus acidilactici PA-1 Alleviates Diet-Induced Obesity by Modulating Hepatic Amino Acid Metabolism and Gut Microbiota in Mice.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- High Burden of Vaginal Infections and Multidrug Resistance With Promising Probiotic Candidates From Cervicovaginal Microbiota in North Region, Cameroon.Probiotics and antimicrobial proteins · 2026Article
- Efficacy ofFrontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Obesity and type 2 diabetes mellitus are global health challenges often associated with disrupted lipid and amino acid metabolism, as well as gut microbiota dysbiosis. Probiotic interventions offer promising potential in ameliorating metabolic disorders, yet strain-specific mechanisms remain to be elucidated. In this study, a canine-derived Pediococcus acidilactici PA-1 was subjected to in vitro evaluation for probiotic properties, and its anti-obesity effects were investigated in high-fat diet (HFD)-induced obese mice. In vitro, PA-1 exhibited safety and favorable probiotic activity including gastrointestinal tolerance, adhesion potential, bile salt hydrolase activity, α-glucosidase inhibition and fatty acid absorption. In vivo, PA-1 supplementation significantly alleviated body weight gain, hepatic steatosis, and lipid accumulation in HFD-fed mice. Multi-omics analyses of liver revealed that PA‑1 modulated hepatic amino acid metabolism at the pathway level (e.g., alanine, aspartate and glutamate metabolism), and led to significant decreases in D‑serine, glycine, and L‑proline in the targeted panel, whereas several others (e.g., L‑aspartate, L‑alanine) showed trend-level decreases. PA‑1 concomitantly suppressed pyruvate flux into the TCA cycle and reduced several TCA intermediates (e.g., fumarate, malate, citrate), eventually Limiting acetyl-CoA availability for de novo Lipogenesis. Additionally, 16S rRNA sequencing demonstrated that PA-1 reshaped the gut microbiota by reducing the Firmicutes/Bacteroidota ratio and enriching the abundance of short-chain fatty acid-producing genera, leading to elevated SCFA concentrations in the cecal contents. This study suggests that PA-1 ameliorates HFD-induced obesity and metabolic disturbances by modulating hepatic amino acid metabolism and gut microbiota composition, highlighting its potential as a functional probiotic for managing obesity-related metabolic disorders.
Indexed as
Identifiers
41114881What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.